Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., announced on February 4, 2025, updates for its innovative obesity treatment candidates, EL-22 and EL-32. Both candidates aim to optimize fat loss while preserving muscle mass in patients undergoing weight loss therapies, including GLP-1 receptor agonists.
For EL-22, Northstrive is finalizing preparations for a pre-Investigational New Drug (pre-IND) meeting request with the FDA, anticipating a Type B meeting in Q2 2025. The company has completed necessary translations and compiled preclinical and clinical inquiries from existing data to support this request.
For EL-32, Northstrive has entered into a research agreement with a leading preclinical contract research organization (CRO) to evaluate the candidate as a monotherapy and in combination with semaglutide in diet-induced obese mice. Northstrive will also present EL-22 at the UCLA Obesity Symposium on February 7, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.